Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

Fig. 4

Biomarker levels in serum during treatment. PRO-C3, C1M, C3M, C4M and VICM levels in serum at baseline (n = 52) and 3 weeks after ipilimumab treatment (n = 52). The black horizontal lines represent the median value of the patients. Serum levels were compared using Wilcoxon matched-pairs rank test. Asterisks indicate the following: **, p < 0.01 and ****, p < 0.0001

Back to article page